Kirin Brewery Introduces Pneumococcal Antigens from Intercell AG, Accelerates Research on Antibody Drug Development.Tokyo, Japan, Apr 11, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Kirin Brewery and Intercell AG have entered into a strategic alliance whereby Kirin will receive the worldwide exclusive rights to develop, manufacture and sell pneumococcal pneumococcal /pneu·mo·coc·cal/ (-kok´al) pertaining to or caused by pneumococci. antigens identified by Intercell, a Vienna-based company specializing in vaccines development. Accordingly, Kirin aims to accelerate its R&D activities for antibody drugs; in particular, the ones for treating severe infections caused by Streptococcus pneumoniae Streptococcus pneu·mo·ni·ae n. Pneumococcus. Streptococcus pneumoniae Microbiology A pathogenic streptococcus with 90 serotypes associated with pneumonia, bacteremia, meningitis Transmission Person to person Incidence . As an initial step, Kirin will strive to develop human monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). using the antigens as well as its proprietary mouse technologies for human antibody production. In addition, Kirin will make an upfront payment of 4 million euros, milestone payments on development and royalties on future sales to Intercell. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion